BofA Securities on Arcus Biosciences (RCUS): MRK Ph3 miss offers 'mixed' readthrough
Tweet Send to a Friend
BofA Securities analyst Jason Zemansky reiterated a Neutral rating and $25.00 price target on Arcus Biosciences (NYSE: RCUS)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
